DAWN vs. MNKD, ARQT, CSTL, LMAT, BDTX, ALPN, ALKS, PRGO, CRNX, and RARE
Should you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include MannKind (MNKD), Arcutis Biotherapeutics (ARQT), Castle Biosciences (CSTL), LeMaitre Vascular (LMAT), Black Diamond Therapeutics (BDTX), Alpine Immune Sciences (ALPN), Alkermes (ALKS), Perrigo (PRGO), Crinetics Pharmaceuticals (CRNX), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "medical" sector.
Day One Biopharmaceuticals (NASDAQ:DAWN) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability.
MannKind received 541 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. Likewise, 59.87% of users gave MannKind an outperform vote while only 58.18% of users gave Day One Biopharmaceuticals an outperform vote.
MannKind has higher revenue and earnings than Day One Biopharmaceuticals. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks.
Day One Biopharmaceuticals has a beta of -1.52, suggesting that its stock price is 252% less volatile than the S&P 500. Comparatively, MannKind has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.
88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 8.4% of Day One Biopharmaceuticals shares are owned by insiders. Comparatively, 3.0% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
MannKind has a net margin of 3.78% compared to Day One Biopharmaceuticals' net margin of 0.00%. MannKind's return on equity of -3.35% beat Day One Biopharmaceuticals' return on equity.
Day One Biopharmaceuticals currently has a consensus price target of $37.67, indicating a potential upside of 195.42%. MannKind has a consensus price target of $8.00, indicating a potential upside of 78.97%. Given Day One Biopharmaceuticals' higher possible upside, equities research analysts clearly believe Day One Biopharmaceuticals is more favorable than MannKind.
In the previous week, Day One Biopharmaceuticals had 5 more articles in the media than MannKind. MarketBeat recorded 6 mentions for Day One Biopharmaceuticals and 1 mentions for MannKind. Day One Biopharmaceuticals' average media sentiment score of 0.01 beat MannKind's score of 0.00 indicating that Day One Biopharmaceuticals is being referred to more favorably in the media.
Summary
MannKind beats Day One Biopharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Day One Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Day One Biopharmaceuticals Competitors List
Related Companies and Tools
